Search results for "apparato respiratorio"

showing 10 items of 517 documents

Obstructive sleep apnoea in adult patients post-tonsillectomy

2021

Background: The impact of removing the upper airway lymphoid tissue and in particular, tonsillectomy, in adults with OSA has not been demonstrated in large populations. Aims: To compare the severity of OSA and the prevalence of cardiovascular, metabolic and respiratory co-morbidities between patients with OSA who had undergone previous tonsillectomy and those who had not. Methods: The 19,711 participants in this study came from the European sleep apnea database (ESADA) which comprises data from unselected adult patients aged 18–80 years with a history of symptoms suggestive of OSA referred to sleep centers throughout Europe. Results: There were no differences between the two groups in terms…

AdultPediatricsmedicine.medical_specialtymedicine.medical_treatment[SDV]Life Sciences [q-bio]ESADALymphoid tissue overgrowthSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesSleep apnoea0302 clinical medicinemedicineHumansMass indexRespiratory systemTonsillectomySleep Apnea ObstructiveAdult patientsbusiness.industrySleep apneaGeneral MedicineESADA ; Lymphoid tissue overgrowth ; Sleep apnoea ; Tonsillectomy.medicine.diseaseSleep in non-human animalsrespiratory tract diseasesTonsillectomy[SDV] Life Sciences [q-bio]Europe030228 respiratory systemDiabetes Mellitus Type 2Lower prevalenceTonsillectomy.AirwaybusinessSleep030217 neurology & neurosurgery
researchProduct

Exhaled nitric oxide is associated with cyclic changes in sexual hormones

2013

Abstract Background We hypothesized that changes in the levels of sexual hormones during the menstrual cycle influence the concentration of nitric oxide in the exhaled air (FeNO) and alveolar exhaled nitric oxide (CANO). Methods Twelve healthy, non allergic women in their reproductive age (age range 25–37 years) were recruited. Subjects were studied, on alternate days, over the course of their menstrual cycle. At each visit, measurements of FeNO and CANO were performed. Progesterone and 17-β-estradiol concentrations were measured in salivary samples. Results Eight subjects completed the study. The levels of FeNO and CANO were 13 ± 4.7 pbb and 3.5 ± 1.9 pbb, respectively (mean ± SD). The mea…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtymedia_common.quotation_subjectReproductive ageBronchiSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideNitric oxidechemistry.chemical_compoundsexual hormonesInternal medicinemedicineHumansPharmacology (medical)SalivaGeneralized estimating equationMenstrual cycleMenstrual CycleProgesteronemedia_commonEstradiolbusiness.industryBiochemistry (medical)GenderBiomarkerHormonesSexual hormonesPulmonary AlveoliEndocrinologychemistryBreath TestsNon allergicExhaled nitric oxideAirway inflammation; Biomarker; Gender; Hormones; Adult; Breath Tests; Bronchi; Estradiol; Female; Humans; Menstrual Cycle; Nitric Oxide; Progesterone; Pulmonary Alveoli; Saliva; Pulmonary and Respiratory Medicine; Pharmacology (medical); Biochemistry (medical)FemalebusinessHormoneAirway inflammation
researchProduct

Chronic renal failure: a neglected comorbidity of COPD

2009

BACKGROUND: To the best of our knowledge, the association between COPD and chronic renal failure (CRF) has never been assessed. Lean mass is frequently reduced in COPD, and the glomerular filtration rate (GFR) might be depressed in spite of normal serum creatinine (concealed CRF). We investigated the prevalence and correlates of both concealed and overt CRF in elderly patients with COPD. METHODS: We evaluated 356 consecutive elderly outpatients with COPD enrolled in the Extrapulmonary Consequences of COPD in the Elderly Study and 290 age-matched outpatients free from COPD. The GFR was estimated using the Modification of Diet in Renal Disease Study Group equation. Patients were categorized a…

Aged 80 and overMaleComorbidityMiddle AgedSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveCOPD ElderlyCase-Control StudiesCreatininePrevalenceHumansKidney Failure ChronicRegression AnalysisFemaleAgedGlomerular Filtration Rate
researchProduct

Difference in Mortality Risk in Elderly People with Bronchial Obstruction Diagnosed Using a Fixed Cutoff or the Lower Limit of Normal of the FEV1/FVC…

2017

Background: Whether a fixed cutoff or the lower limit of normal of the FEV1/FVC ratio should be used to diagnose bronchial obstruction is still a matter of debate. This issue is particularly important for elderly people. Objectives: We used equations applicable up to 90 years of age to evaluate the mortality of elderly people diagnosed with bronchial obstruction using either a fixed cutoff of 0.7 or the lower limit of normal (LLN). Methods: Participants in the SaRA (Salute Respiratoria nell'Anziano, Italian for "Respiratory Health in the Elderly") study were grouped as follows: FEV1/FVC ≥0.7 and ≥ LLN (n = 535: F-/L-), FEV1/FVC <0.7 but ≥ LLN (n = 118: F+/L-), and FEV1/FVC <0.7 and < LLN (n…

Aged 80 and overMalePulmonary and Respiratory MedicineVital CapacityBronchial obstructionSettore MED/10 - Malattie Dell'Apparato RespiratorioRisk AssessmentLower limit of normalAlgorithmFixed cutoffElderlyItalyForced Expiratory VolumeHumansFemaleLung Diseases ObstructiveAlgorithmsAgedHuman
researchProduct

Effects of chronic airway disease on health status of geriatric patients.

2004

Background and aims: The impact of chronic airway disease on the health status of elderly patients is only to some extent explained by indexes of airflow limitation. The present study was designed to assess to what extent: 1) asthma, chronic obstructive pulmonary disease (COPD) and chronic bronchitis with normal FEV1 (simple bronchitis) differ in their impact on health status; 2) health status depends upon non-respiratory factors. Methods: A total of 1601 outpatients over 65 - 198 with asthma, 228 with COPD, 91 with simple bronchitis, and 1084 with non-respiratory illnesses (control group) -were studied by collection of five health status indexes and multidimensional assessment. Discriminan…

AgingChronic bronchitismedicine.medical_specialtyHealth StatusSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveInternal medicinemedicineHealth Status IndicatorsHumansRespiratory functionBronchitisAsthmaAgedCOPDbusiness.industryAnthropometrymedicine.diseaseComorbidityAsthmarespiratory tract diseasesAirway diseaseChronic DiseasePhysical therapyBronchitisaging quality of life COPDGeriatrics and GerontologybusinessAlgorithmsAging clinical and experimental research
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Diagnosis and management of asthma in the elderly.

2013

Bronchial asthma is one of the most common chronic diseases worldwide, and by definition not expected to recover with aging. However, the concept that asthma can affect older individuals has been largely denied in the past. In clinical practice, asthma that occurs in the most advanced ages is often diagnosed as COPD, thus leading to undertreatment or improper treatment. The heterogeneity of clinical and functional presentation of geriatric asthma, including the partial loss of reversibility and of the allergic component, contributes to this misconception. A large body of evidence has accumulated demonstrating that the prevalence of asthma in the most advanced ages is similar to that in youn…

Agingmedicine.medical_specialtyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Human lungMedication AdherenceOlder patientsPartial lossInternal MedicinemedicineHumansAnti-Asthmatic AgentsIntensive care medicineAsthmaAgedCOPDbusiness.industryAsthma treatmentAge Factorsmedicine.diseaseComorbidityLung functionAsthmarespiratory tract diseasesClinical Practicemedicine.anatomical_structurePhysical therapybusinessAirway inflammationEuropean journal of internal medicine
researchProduct

Challenges in the pharmacological treatment of geriatric asthma

2016

ABSTRACTAsthma in older populations is characterized by frequent comorbid conditions, which increase the risk of side effects and of detrimental interactions between respiratory and non-respiratory drugs. These observations lead to the need to manage asthma in older populations by applying a multidimensional assessment and a multidisciplinary treatment; therefore, we favor the use of the ‘geriatric’ term to define asthma in the elderly. Geriatric asthma is a complex disease, which may not necessarily imply that it is also complicated, although the two conditions may often coexist. On this basis, the switch from an organ-driven management to the holistic approach may be the key factor to att…

Agingmedicine.medical_specialtyComplex diseaseComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentPharmacological treatmentOlder population03 medical and health sciences0302 clinical medicineMultidisciplinary approachAnimalsHumansMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicinePsychiatryAgedAsthmabusiness.industryAge FactorsGeneral Medicinemedicine.diseaseComorbidityAsthmaInhaled treatment030228 respiratory systemAdherencePharmacology Toxicology and Pharmaceutics (all)businessExpert Review of Clinical Pharmacology
researchProduct

Comorbidities of Lung Disease in the Elderly

2017

Comorbidities are common in elderly individuals with chronic respiratory diseases. They can affect disease manifestations and severity and can even impact management. Comorbidities can affect the treatment of the lung disease, particularly because of the interaction with the respiratory drugs. Thus, a multidimensional approach with multidisciplinary intervention is suggested for elderly respiratory patients, switching from a disease-oriented scheme to a dysfunction-oriented approach. Unfortunately, older individuals are often excluded from clinical trials because of advanced age and comorbidities. This article reviews the role of comorbidities in the management of respiratory diseases in th…

Agingmedicine.medical_specialtyRespiratory Tract DiseasesComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineHumansSenile lung030212 general & internal medicineRespiratory systemIdiopathic lung fibrosiIntensive care medicineRespiratory Tract DiseaseAgedAsthmabusiness.industryChronic obstructive pulmonary diseasefood and beveragesmedicine.diseaseComorbidityAsthmaPatient Care ManagementClinical trial030228 respiratory systemLung diseaseGeriatrics and GerontologybusinessHumanClinics in Geriatric Medicine
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct